13:20 Wed 18 Nov 2020
Novacyt S.A. - Director/PDMR Shareholding
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
| a) | Name |
| ||||||||
| 2. | Reason for the Notification | |||||||||
| a) | Position/status | PCA to
| ||||||||
| b) | Initial notification/ Amendment | Initial Notification
| ||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Novacyt S.A. | ||||||||
| b) | LEI | 213800BWAC2BF295EG28 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the Financial instrument, type of instrument | ordinary shares of
| ||||||||
| | Identification code | FR0010397232 | ||||||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares
| ||||||||
| c) | Price(s) and volume(s) |
| ||||||||
| d) | Aggregated information: · Aggregated volume · Price |
| ||||||||
| e) | Date of the transaction |
| ||||||||
| f) | Place of the transaction | London Stock Exchange, AIM | ||||||||
Contacts
Novacyt SA
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto /
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com; y.petit@allegrafinance.com
FTI Consulting (International)
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information please refer to the website: www.novacyt.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
